Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
CELEBRATION, Fla. - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a company specializing in therapies for rare diseases and showing impressive revenue growth of 46.47% over the last twelve months, announced the re-election of Wendy L. Dixon, Ph.D., and Tamara A. Favorito to its Board of Directors. According to InvestingPro analysis, the company maintains a strong financial position with a current ratio of 3.02, indicating robust liquidity. The re-election took place during the firm’s 2025 Annual Meeting of Stockholders, with stockholders voting to extend their tenure as Class I Directors until the 2028 Annual Meeting.
The company’s board expressed gratitude towards stockholders for their participation and support, interpreting the vote as an endorsement of Zevra’s strategic direction. The confidence appears well-placed, as InvestingPro data shows the company has delivered an impressive 81.28% return over the past year. Over the last two years, the company has been working on transforming into a growth-oriented commercial organization with the aim of positively impacting patients with rare diseases. Analysts are optimistic about the company’s trajectory, with multiple upward earnings revisions for the upcoming period.
An attempted nomination of alternative directors by stockholder Daniel J. Mangless was disregarded due to non-compliance with Securities and Exchange Commission (SEC) proxy rules and the company’s bylaws. Mangless did not fulfill the requirement to solicit a minimum of 67% of the voting power nor did he attend the Annual Meeting to present his nominees, resulting in his nominations being invalidated.
The official vote count showed that Dixon and Favorito received 73.97% and 73.41% of the votes, respectively, significantly more than the votes for Mangless’s nominees, had they been valid. This outcome reaffirms the stockholder support for the current board, which prides itself on industry expertise and commitment to value delivery.
In addition to the board elections, stockholders approved Ernst & Young LLP as the company’s independent auditors for the fiscal year ending December 31, 2025. The final certified results will be reported on a Form 8-K with the SEC.
Zevra Therapeutics continues to focus on creating therapies for rare diseases, leveraging science, data, and patient needs. The company’s mission is to bring transformative treatments to individuals with rare diseases, often where limited or no other treatment options exist. With a gross profit margin of 78.84% and analysts forecasting profitability this year, the company shows promising financial metrics. For deeper insights into Zevra’s financial health and growth potential, investors can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research reports. Zevra operates expanded access programs, subject to its policy and local jurisdiction laws, providing therapies to eligible patients as determined by their treating physicians.
This article is based on a press release statement from Zevra Therapeutics.
In other recent news, Zevra Therapeutics announced its financial results for the first quarter of 2025, reporting a net loss of $3.1 million, or $0.06 per share. The company generated $20.4 million in revenue, primarily driven by its MyPlifa product, exceeding the forecasted $16.02 million. Despite the net loss, Zevra’s earnings per share outperformed expectations, which had anticipated a loss of $0.24 per share. The company is advancing its European regulatory submissions for MyPlifa, aiming to expand its market presence. Zevra also highlighted its ongoing commercial launches and clinical trials, including the Phase III DISCOVER trial for saliprolol. The company’s strategic initiatives and product performance have garnered positive investor sentiment. Additionally, Zevra’s cash position was strengthened by $148.3 million from a PRV sale, providing financial flexibility for future endeavors. The company continues to focus on cost management, with a $600,000 year-over-year reduction in operating expenses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.